This Study Aims to Find and Test a Safe Dose of BI 905677 in Patients With Different Types of Cancer (Solid Tumours)
NCT03604445
·
clinicaltrials.gov ↗
PHASE1
Phase
TERMINATED
Status
37
Enrollment
INDUSTRY
Sponsor class
Stopped
Sponsor decision
Conditions
Neoplasms
Interventions
DRUG:
BI 905677
Sponsor
Boehringer Ingelheim